O Shaughnessy Asset Management LLC Has $29.31 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

O Shaughnessy Asset Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 53.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 317,302 shares of the biopharmaceutical company's stock after acquiring an additional 110,056 shares during the quarter. O Shaughnessy Asset Management LLC's holdings in Gilead Sciences were worth $29,309,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Walled Lake Planning & Wealth Management LLC grew its position in shares of Gilead Sciences by 1.4% in the fourth quarter. Walled Lake Planning & Wealth Management LLC now owns 85,435 shares of the biopharmaceutical company's stock valued at $7,892,000 after purchasing an additional 1,165 shares during the last quarter. Brandywine Global Investment Management LLC increased its holdings in shares of Gilead Sciences by 330.8% during the 4th quarter. Brandywine Global Investment Management LLC now owns 740,097 shares of the biopharmaceutical company's stock worth $68,363,000 after purchasing an additional 568,319 shares during the period. CIBC Private Wealth Group LLC raised its position in shares of Gilead Sciences by 7.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 45,205 shares of the biopharmaceutical company's stock valued at $4,030,000 after buying an additional 2,983 shares during the last quarter. IPG Investment Advisors LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $217,000. Finally, Summit Securities Group LLC grew its position in Gilead Sciences by 942.7% during the fourth quarter. Summit Securities Group LLC now owns 21,897 shares of the biopharmaceutical company's stock worth $2,023,000 after buying an additional 19,797 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Remove Ads

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Trading Down 0.7 %

Shares of GILD traded down $0.77 on Tuesday, reaching $111.28. 6,284,006 shares of the company's stock were exchanged, compared to its average volume of 7,301,817. The business has a 50 day moving average price of $105.88 and a two-hundred day moving average price of $95.20. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The stock has a market capitalization of $138.58 billion, a P/E ratio of 300.76, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Oppenheimer raised their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. Morgan Stanley boosted their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, March 11th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Finally, Piper Sandler upped their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.